[89Zr]Zr- BI 770371

N/A

Report date: 2026/03/23 20:03:44

Base Information

Drug Name[89Zr]Zr- BI 770371

Drug Alias Name[89Zr]Zr- BI 770371

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibodyRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Nuclides > Zirconium > 89Zr +[6]

Mechanisms of ActionT lymphocytes stimulantsAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsCheckpoint kinase inhibitors

TargetsCheckpoint kinase

Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungSquamous Cell Carcinoma of Head and NeckMelanoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryNetherlands

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesC.H. Boehringer Sohn Ag & Co. Kg

China Registration ClassN/A

Develop Information

Active CompaniesC.H. Boehringer Sohn Ag & Co. Kg

Inactive CompaniesN/A

Active IndicationsCarcinoma, Non-Small-Cell LungSquamous Cell Carcinoma of Head and NeckMelanoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A